Treatment for Nonasthmatic Eosinophilic Bronchitis
Inhaled corticosteroids are the first-line treatment for nonasthmatic eosinophilic bronchitis, with budesonide 200 μg twice daily administered for at least 2-3 months to minimize relapse rates 1, 2.
First-Line Treatment Algorithm
Start with inhaled corticosteroids immediately upon diagnosis of NAEB 1. The evidence strongly supports:
- Budesonide 200 μg twice daily as the standard initial dose 2
- Minimum treatment duration of 2-3 months is critical—the 1-month treatment group showed a 41.9% relapse rate versus only 12.0% in the 3-month group at 1-year follow-up 2
- Treatment duration is inversely correlated with relapse rates 3
The CHEST guideline provides a Grade 2B recommendation for ICS as first-choice treatment, though acknowledges the evidence base includes only small therapeutic trials 1.
Step-Up Therapy for Incomplete Response
If cough persists after initial ICS treatment:
- First, reconsider alternative diagnoses before escalating therapy 1
- Increase the inhaled corticosteroid dose 1
- Add a leukotriene receptor antagonist as a therapeutic trial 1
- Consider oral corticosteroids for persistent disease 3, 4
This step-wise approach carries a Grade 2C recommendation, reflecting the limited trial data in NAEB specifically 1.
Important Clinical Considerations
Duration matters more than you might expect: The randomized trial data clearly demonstrates that stopping ICS too early leads to high relapse rates—cutting treatment short at 1 month nearly quadruples your relapse risk compared to 3 months of therapy 2. This is a common pitfall in clinical practice where providers may discontinue treatment once symptoms resolve.
Emerging therapies: Anti-IL-5 biologics show promise for refractory cases, though this remains investigational 3. Unlike asthma where anti-IL-5 has failed to modify cough, NAEB may represent a different therapeutic target given its distinct pathophysiology 4.
Environmental triggers: If occupational exposure or specific allergen inhalation is identified as the cause, removing the trigger is essential alongside anti-inflammatory therapy 5.
Monitoring Response
Expect significant improvement within days to weeks of starting ICS 6. The treatment effectively reduces:
- Cough visual analogue scale scores
- Cough symptom scores
- Sputum eosinophilia 2
Note on bronchodilators: While approximately one-third of NAEB patients show response to bronchodilators (related to lower cough reflex sensitivity), this is not standard first-line therapy 7. The guideline does not recommend beta-agonists for NAEB as it does for asthma 1.